Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $105.00

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective lifted by Wedbush from $103.00 to $105.00 in a research report released on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Other equities analysts have also issued reports about the company. Raymond James Financial raised Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from $63.00 to $123.00 in a report on Tuesday, March 10th. Wells Fargo & Company began coverage on shares of Dianthus Therapeutics in a report on Thursday, March 19th. They issued an “overweight” rating and a $135.00 price objective for the company. Oppenheimer lifted their price objective on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research note on Monday, March 9th. Jefferies Financial Group set a $98.00 target price on shares of Dianthus Therapeutics and gave the company a “buy” rating in a report on Monday, March 9th. Finally, Truist Financial increased their target price on Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Dianthus Therapeutics has a consensus rating of “Buy” and a consensus target price of $117.82.

Dianthus Therapeutics Price Performance

Shares of Dianthus Therapeutics stock opened at $86.84 on Wednesday. Dianthus Therapeutics has a 1 year low of $16.64 and a 1 year high of $96.50. The stock has a fifty day moving average price of $81.01 and a 200-day moving average price of $56.30. The firm has a market cap of $4.75 billion, a PE ratio of -21.03 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The business had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. As a group, equities analysts anticipate that Dianthus Therapeutics will post -3.95 EPS for the current fiscal year.

Insider Activity

In related news, CEO Marino Garcia sold 122,918 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Ryan Savitz sold 8,224 shares of the stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $89.84, for a total transaction of $738,844.16. Following the completion of the sale, the executive vice president owned 8,224 shares in the company, valued at $738,844.16. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 323,021 shares of company stock valued at $26,564,008. Corporate insiders own 3.02% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in DNTH. PNC Financial Services Group Inc. raised its position in shares of Dianthus Therapeutics by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after buying an additional 139 shares in the last quarter. First Horizon Corp purchased a new position in Dianthus Therapeutics during the first quarter worth about $32,000. Virtus Investment Advisers LLC increased its stake in Dianthus Therapeutics by 7.1% in the 4th quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after acquiring an additional 416 shares during the last quarter. Parkside Financial Bank & Trust increased its stake in Dianthus Therapeutics by 131.7% in the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after acquiring an additional 540 shares during the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of Dianthus Therapeutics by 36.9% in the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after acquiring an additional 542 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Key Headlines Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Dianthus Therapeutics and set a $130 price target, suggesting meaningful upside from current levels.
• Positive Sentiment: The firm raised several earnings estimates for Dianthus Therapeutics, including FY2026 EPS to ($4.81) from ($6.21) and FY2027 EPS to ($5.49) from ($6.04), which may be viewed as improved outlook revisions.
• Neutral Sentiment: HC Wainwright also updated quarterly EPS forecasts for Q2 2026, Q3 2026, Q4 2026, and multiple 2027 quarters, but these remain negative EPS estimates as the company is still expected to be unprofitable.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.